m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04356)
Name
Bivatuzumab mertansine
Synonyms
BIWI-1; Bivatuzumab-DM1
    Click to Show/Hide
Status
Terminated
TTD Drug ID
D0R6EQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Extracellular matrix receptor III (CD44)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). [1], [2]
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). [2], [3]
References
Ref 1 Roles of the m(6)A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol. 2022 Apr 26;13:798583. doi: 10.3389/fimmu.2022.798583. eCollection 2022.
Ref 2 A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. doi: 10.1158/1078-0432.CCR-06-0910.
Ref 3 The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2. J BUON. 2021 Mar-Apr;26(2):444-449.